Glimisave M 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The synergistic action of these two agents effectively controls hyperglycemia by addressing both insulin secretion and insulin resistance. Glimisave M 2 Tablet PR is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately managed by monotherapy. It is essential to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, especially in elderly patients or those with renal impairment. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Patients should be advised to report any signs of lactic acidosis, a rare but serious adverse effect associated with metformin. This medication should be used under strict medical supervision, with periodic assessment of renal function and adherence to lifestyle modifications for optimal therapeutic outcomes.